1. Tafuri A, Andreeff M (1990) Kinetic rationale for cytokine-induced recruitment of myeloblastic leukemia followed by cycle-specific chemotherapy in vitro. Leukemia 4:826–834.
http://www.ncbi.nlm.nih.gov/pubmed/2243506
2. te Boekhorst PA et al (1993) Enhanced chemosensitivity of clonogenic blasts from patients with acute myeloid leukemia by G-CSF, IL-3 or GM-CSF stimulation. Leukemia 7:1191–1198.
http://www.ncbi.nlm.nih.gov/pubmed/7688839
3. Saito K et al (2000) Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with AML, secondary AML, and refractory anemia with excess blasts in transformation. Int J Hematol 71:238–244.
http://www.ncbi.nlm.nih.gov/pubmed/10846828
4. Li X et al (2015) Efficacy of cytarabine, aclarubicin and granulocyte colony-stimulating factor (CAG) regimen compared to FLAG regimen for adult patients with relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia. Leuk Res.
https://doi.org/10.1016/j.leukres.2015.08.013
5. Ornstein MC et al (2015) More is better: Combination therapies for myelodysplastic syndromes. Best Practice Res Clin Haematol 28:22–31.
https://doi.org/10.1016/j.beha.2014.11.002